![Logo IRB](https://prodcraftsa01.blob.core.windows.net/assets/products/irb-advisor/_contentImage/logo-IRB_2022-06-13-214633_aeuk.png)
IRB Advisor – August 1, 2005
August 1, 2005
View Issues
-
How much is too much? Many IRBs lack guidelines for paying research subjects
When an IRB reviews a proposal to pay research participants, members often have little more guidance to go on than their own gut feeling of what is appropriate and what is too much. -
HIV study involving foster children raises questions
Recent revelations that hundreds of HIV-positive foster children may have been signed up for clinical trials without advocates assigned to ensure their safety have stirred the latest controversy regarding pediatric clinical research. -
Future insurability is an issue for genetic subjects
The largest study yet of public fears about genetic discrimination found that 40% of people undergoing testing for a particular genetic disease were concerned that their participation could affect future access to insurance. -
Lack of information may be behind low participation
Many people willing to participate in clinical research trials never do because they simply dont know about them or misunderstand the obligations involved, says a leading expert on supporting public research participation. -
OHRP effort rubs some the wrong way
The new public outreach campaign by the OHRP is a much-needed step in the right direction, say many clinical researchers. But the campaigns centerpiece an educational pamphlet designed to answer basic questions about research participation is leaving nonclinical researchers feeling left out in the cold. -
South Korean team makes patient-specific stem cells
Last year, South Korean researcherWoo Suk Hwang and colleagues at Seoul National University stunned the world with news first published in Science on-line that they had developed stem cells from a cloned human embryo, using somatic-cell nuclear transfer.